Pavel Moudrý

2.6k total citations · 1 hit paper
18 papers, 1.3k citations indexed

About

Pavel Moudrý is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Pavel Moudrý has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Oncology and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in Pavel Moudrý's work include DNA Repair Mechanisms (11 papers), Cancer-related Molecular Pathways (4 papers) and PARP inhibition in cancer therapy (4 papers). Pavel Moudrý is often cited by papers focused on DNA Repair Mechanisms (11 papers), Cancer-related Molecular Pathways (4 papers) and PARP inhibition in cancer therapy (4 papers). Pavel Moudrý collaborates with scholars based in Czechia, Denmark and Sweden. Pavel Moudrý's co-authors include Jiří Bártek, Robert Strauss, Apolinar Maya‐Mendoza, Joanna Maria Merchut‐Maya, Myunghee Lee, Martin Mistrík, Jiřina Bártková, Jiří Bártek, Zdeněk Hodný and Matthew Lacey and has published in prestigious journals such as Nature, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Pavel Moudrý

17 papers receiving 1.3k citations

Hit Papers

High speed of fork progression induces DNA replication st... 2018 2026 2020 2023 2018 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pavel Moudrý Czechia 14 957 512 209 125 118 18 1.3k
Shilpee Dutt India 21 902 0.9× 295 0.6× 199 1.0× 269 2.2× 154 1.3× 48 1.5k
Megan Keniry United States 17 1.2k 1.3× 318 0.6× 233 1.1× 106 0.8× 80 0.7× 38 1.5k
Gretchen Poortinga Australia 18 1.7k 1.8× 336 0.7× 149 0.7× 144 1.2× 65 0.6× 31 2.0k
Jan van Riggelen United States 17 1.3k 1.4× 483 0.9× 333 1.6× 201 1.6× 74 0.6× 20 1.7k
Wojciech Michowski United States 16 817 0.9× 271 0.5× 150 0.7× 86 0.7× 52 0.4× 20 1.1k
Amila Suraweera Australia 16 1.3k 1.4× 302 0.6× 155 0.7× 79 0.6× 69 0.6× 25 1.6k
Jolly Mazumdar United States 11 893 0.9× 508 1.0× 497 2.4× 128 1.0× 102 0.9× 16 1.5k
Nathaniel Robichaud Canada 12 1.6k 1.6× 266 0.5× 252 1.2× 205 1.6× 91 0.8× 14 1.9k
Markus E. Diefenbacher Germany 23 1.4k 1.5× 567 1.1× 296 1.4× 186 1.5× 74 0.6× 42 1.9k
Andréa Barretto Motoyama Brazil 13 1.1k 1.1× 568 1.1× 481 2.3× 164 1.3× 56 0.5× 28 1.7k

Countries citing papers authored by Pavel Moudrý

Since Specialization
Citations

This map shows the geographic impact of Pavel Moudrý's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavel Moudrý with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavel Moudrý more than expected).

Fields of papers citing papers by Pavel Moudrý

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavel Moudrý. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavel Moudrý. The network helps show where Pavel Moudrý may publish in the future.

Co-authorship network of co-authors of Pavel Moudrý

This figure shows the co-authorship network connecting the top 25 collaborators of Pavel Moudrý. A scholar is included among the top collaborators of Pavel Moudrý based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavel Moudrý. Pavel Moudrý is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Moudrý, Pavel, et al.. (2025). The need for speed: drivers and consequences of accelerated replication forks. Communications Biology. 8(1). 1538–1538.
2.
Moudrý, Pavel, et al.. (2024). DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps. Nature Communications. 15(1). 7375–7375. 6 indexed citations
3.
Škrott, Zdeněk, Ján Gurský, Jaroslav Bačovský, et al.. (2022). A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death and Disease. 13(3). 203–203. 12 indexed citations
4.
Moudrý, Pavel, et al.. (2022). Emetine blocks DNA replication via proteosynthesis inhibition not by targeting Okazaki fragments. Life Science Alliance. 5(12). e202201560–e202201560. 3 indexed citations
5.
Moudrý, Pavel, et al.. (2021). RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. Cell Death and Differentiation. 29(3). 687–696. 20 indexed citations
6.
Lacey, Matthew, et al.. (2019). Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. Aging. 11(8). 2512–2540. 137 indexed citations
7.
Maya‐Mendoza, Apolinar, Pavel Moudrý, Joanna Maria Merchut‐Maya, et al.. (2018). High speed of fork progression induces DNA replication stress and genomic instability. Nature. 559(7713). 279–284. 356 indexed citations breakdown →
9.
Oždian, Tomáš, Zuzana Macečková, Lakshman Varanasi, et al.. (2017). Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. Journal of Proteomics. 162. 73–85. 30 indexed citations
10.
Mistrík, Martin, Pavel Moudrý, Ján Gurský, et al.. (2016). Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene. 36(17). 2405–2422. 44 indexed citations
11.
Moudrý, Pavel, Kenji Watanabe, Kamila Wolanin, et al.. (2016). TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. The Journal of Cell Biology. 212(3). 281–288. 60 indexed citations
12.
Frankum, Jessica, Pavel Moudrý, Rachel Brough, et al.. (2015). Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget. 6(13). 10746–10758. 16 indexed citations
13.
Moudrý, Pavel, Claudia Lukas, Libor Macůrek, et al.. (2012). Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle. 11(8). 1573–1582. 80 indexed citations
14.
Hamerlik, Petra, Justin D. Lathia, Rikke Rasmussen, et al.. (2012). Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. The Journal of Experimental Medicine. 209(3). 507–520. 330 indexed citations
15.
Hamerlik, Petra, Justin D. Lathia, Rikke Rasmussen, et al.. (2012). Autocrine VEGF-VEGFR2—Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. The Journal of Cell Biology. 196(6). i9–i9. 21 indexed citations
16.
Moudrý, Pavel, Claudia Lukas, Libor Macůrek, et al.. (2011). Nucleoporin NUP153 guards genome integrity by promoting nuclear import of 53BP1. Cell Death and Differentiation. 19(5). 798–807. 58 indexed citations
17.
Bártková, Jiřina, Pavel Moudrý, Zdeněk Hodný, et al.. (2010). Heterochromatin marks HP1γ, HP1α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours. International Journal of Andrology. 34(4pt2). e103–13. 15 indexed citations
18.
Blažková, Hana, Kateřina Krejčíková, Pavel Moudrý, et al.. (2009). Bacterial intoxication evokes cellular senescence with persistent DNA damage and cytokine signalling. Journal of Cellular and Molecular Medicine. 14(1-2). 357–367. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026